Organization (Industry)
BIOCODEX
ClinicalTrials.gov lists BIOCODEX as lead sponsor of 19 trials. It has 14 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BIOCODEX: 19 lead-sponsored trials and 2 legal-entity registrations. The parent company on record for BIOCODEX is PHARCOR, which does not have its own page on this site.
Disease areas (20)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Epilepsies, Myoclonic | 2 |
| Epilepsy | 2 |
| Hyperoxaluria | 2 |
| Hyperoxaluria, Primary | 2 |
| Irritable Bowel Syndrome | 2 |
Showing 5 of 20 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 4 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 3 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (14)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Saccharomyces Boulardii 250 MG | Irritable Bowel Syndrome | Phase 3 | 1 |
| Urine samples collect | Hyperoxaluria | Phase 3 | 1 |
| Urine samples collect | Hyperoxaluria, Primary | Phase 3 | 1 |
| Saccharomyces Boulardii 250 MG | Ichthyosis | Phase 3 | 1 |
| Saccharomyces Boulardii 250 MG | Ichthyosis Bullosa of Siemens | Phase 3 | 1 |
Showing 5 of 14 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Stiripentol | 3 |
| Probiotic : Saccharomyces boulardii | 1 |
| Probiotic : Bacillus clausii | 1 |
| Stool samples | 1 |
| Amoxicillin + Saccharomyces boulardii CNCM I-745 | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 44% hit target (n=9) | 25% on time (n=8) |
Journals published in (10)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Gut microbes | 2 |
| British journal of anaesthesia | 1 |
| Clinical medicine insights. Pediatrics | 1 |
| European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology | 1 |
| European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | 1 |
Showing 5 of 10 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 15 | 2 | 2024-01-16 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 3 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 20 | 2026-04-30 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Biocodex | Beauvais, FR | EMA, FDA, Health Canada |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Exystat | Co sponsors trial with | 1 |
| Neurodesarrollo Quito | Co sponsors trial with | 1 |
Latest dated events (62)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-30 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-12-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 62 events.
Biomarker capability evidence (10)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CIC | Trial sponsor | Named in trial inclusion criteria |
| CYP1A2 | Trial sponsor | Named in trial exclusion criteria |
| CYP2C19 | Trial sponsor | Named in trial exclusion criteria |
| CYP3A4 | Trial sponsor | Named in trial exclusion criteria |
| GLB1 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 10 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.